US · PLSE
Pulse Biosciences, Inc.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Miami, CA 94545
- Website
- pulsebiosciences.com
Price · as of 2025-12-31
$20.83
Market cap 1.27B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $18.21 | ||||
| 2017 | $17.36 | ||||
| 2018 | $16.95 | ||||
| 2019 | $7.74 | ||||
| 2020 | $30.87 | ||||
| 2021 | $4.44 | ||||
| 2022 | $3.47 | $27.82 | $0.00 | $0.00 | $69.43 |
| 2023 | $9.64 | $37.09 | |||
| 2024 | $17.37 | ||||
| 2025 | $18.85 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Pulse Biosciences, Inc.'s (PLSE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $20.83
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PLSE | Pulse Biosciences, Inc. | $20.83 | 1.27B | — | — | — | — | -17.46 | 15.75 | 3629.72 | -16.69 | -100.37 | 16.44 | -360.00% | -21982.57% | -20794.57% | -74.45% | -1168.13% | -63.68% | 0.09 | — | 10.53 | 10.22 | 1.02 | 1739.00% | — | 4927.00% | -4.29% | -6.83 | -826.49% | 0.00% | 0.00% | 0.00% | -15.56 | -21.99 | 3420.56 | 40.87 |
| ATAI | Atai Beckley N.V | $3.63 | 684.71M | +564% | -83% | — | — | -1.61 | 2.08 | 785.20 | -1.41 | -0.59 | 2.15 | 100.00% | -33341.23% | -48463.96% | -83.53% | -126.85% | -66.27% | 0.21 | -32.87 | 3.21 | 2.55 | -0.05 | 27200.00% | -191.00% | -257.00% | -34.13% | -3.30 | -102.19% | 0.00% | 0.00% | 0.00% | -1.99 | -2.47 | 663.04 | -4.47 |
| BBNX | Beta Bionics, Inc. | $12.63 | 560.55M | +248% | +7,672% | — | — | -6.93 | 1.76 | 5.06 | -4.11 | — | 1.76 | 55.40% | -71.50% | -73.02% | -40.26% | -236.00% | -30.60% | 0.04 | — | 8.66 | 7.64 | 0.26 | -7895.00% | 5394.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | -4.20 | — | 3.00 | 6.28 |
| DNTH | Dianthus Therapeutics, In… | $55.19 | 2B | -29% | -75% | — | — | -9.42 | 2.27 | 128.39 | -5.19 | — | 2.27 | 100.00% | -1633.74% | -1362.77% | -32.60% | -273.59% | -30.71% | 0.00 | — | 15.22 | 14.96 | 0.21 | -6982.00% | 12063.00% | 11175.00% | -9.78% | -4.24 | -210.26% | 0.00% | 0.00% | 0.00% | -5.17 | -6.73 | 84.49 | 21.62 |
| IMTX | Immatics N.V. | $10.34 | 1.39B | +1,496% | -51% | -32% | +199% | 28.44 | 0.75 | 2.78 | -4.51 | — | 0.76 | 100.00% | -24.78% | 9.77% | 3.80% | 27.69% | 2.52% | 0.03 | -43.58 | 9.26 | 8.99 | -6.40 | -11167.00% | 18860.00% | 127096.00% | -40.32% | -2.32 | 175.55% | 0.00% | 0.00% | 4.04% | 4.03 | 0.89 | -1.00 | 1.96 |
| KMTS | KESTRA MEDICAL TECHNOLOGI… | $23.28 | 1.36B | +67% | +283% | — | — | -6.49 | 3.60 | 12.35 | -5.57 | -4.28 | 3.60 | 40.47% | -177.85% | -190.28% | 5732.26% | 132.69% | -66.62% | 0.22 | -13.75 | 6.72 | 6.47 | 1.97 | 15147.00% | 11505.00% | 1941.00% | -13.70% | -2.04 | 126.23% | 0.22% | -1.50% | 31.39% | -5.13 | -5.39 | 9.12 | 2.34 |
| LFMD | LifeMD, Inc. | $2.67 | 128.52M | +1,008% | +2,300% | — | — | -10.27 | -35.07 | 0.91 | -27.43 | — | -9.02 | 88.67% | -7.60% | -8.89% | 1891.64% | 123.73% | -28.61% | -4.58 | -7.40 | 0.81 | 0.72 | 1.49 | -2429.00% | 3927.00% | 677408.00% | 3.11% | 0.29 | -45.81% | 1.61% | -16.60% | 1.61% | -11.30 | 30.53 | 0.86 | -1.05 |
| NKTR | Nektar Therapeutics | $68.98 | 1.4B | -92% | -92% | — | — | -1.52 | 2.98 | 1.84 | -0.33 | — | 2.98 | 68.82% | -106.88% | -120.86% | -124.10% | 143.06% | -33.90% | 1.69 | -3.74 | 4.26 | 4.18 | -0.67 | -6017.00% | 922.00% | -842.00% | -97.90% | -2.86 | 241.42% | 0.00% | 0.00% | 15.02% | -0.27 | -0.16 | 0.29 | -16.15 |
| NVCR | NovoCure Limited | $13.67 | 1.53B | +107% | -55% | — | — | -11.06 | 4.43 | 2.30 | -11.25 | — | 4.43 | 74.54% | -23.47% | -20.79% | -38.89% | -119.85% | -13.32% | 0.85 | — | 2.90 | 2.57 | -1.57 | -2179.00% | 828.00% | 932.00% | -5.02% | -0.22 | -58.98% | 0.00% | 0.00% | 22.09% | -8.71 | -17.70 | 2.04 | 0.52 |
| OPK | OPKO Health, Inc. | $1.20 | 921.24M | +2,047% | -57% | — | +48% | -4.21 | 0.75 | 1.56 | -20.44 | -1.44 | 3.55 | 61.01% | -36.08% | -37.20% | -17.14% | -14.89% | -10.92% | 0.33 | -2.16 | 3.97 | 3.13 | -0.89 | 29113.00% | -1490.00% | -848.00% | -20.10% | -1.22 | -13.88% | 0.00% | 0.00% | 3.09% | -4.53 | -5.20 | 1.64 | -0.35 |
| STAA | STAAR Surgical Company | $19.90 | 982.38M | +92% | -59% | -70% | — | -44.58 | 2.27 | 2.87 | -123.99 | — | 2.28 | 76.32% | -4.02% | -6.44% | -5.16% | -6.20% | -4.05% | 0.10 | — | 5.23 | 4.41 | 18.43 | -19535.00% | -264.00% | 11338.00% | -0.85% | 0.22 | -3.77% | 0.00% | 0.00% | 0.17% | -56.24 | -92.48 | 2.26 | 5.87 |
About Pulse Biosciences, Inc.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
- CEO
- Paul Arthur LaViolette
- Employees
- 75
- Beta
- 1.80
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $20.83) − 1 = — (DCF, example).